Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Safety Considerations for HIV Treatments During Pregnancy

Listen to expert insights from Dr. Jean Rene Anderson and Dr. William Short on their approach to optimizing HIV treatments during pregnancy.
Jean Rene Anderson, MD
William R. Short, MD, MPH, AAHIVS
Released: August 23, 2022

In this episode, hear Dr. Jean Rene Anderson and Dr. William Short discuss special factors to consider when selecting HIV treatments during pregnancy, including:

  • Key elements involved in evaluating ARV medications during pregnancy (eg, efficacy, pharmacokinetic, and safety data)
  • Approach to optimizing ART regimens prior to and during pregnancy

Information on this Educational Activity

Faculty

Jean Rene Anderson, MD

Professor
Department of Gynecology and Obstetrics
Johns Hopkins University
Director, Johns Hopkins HIV Women's Health Program
Johns Hopkins Medical Institutions
Baltimore, Maryland

Jean Rene Anderson, MD: researcher: Gilead Sciences; individual publicly traded stocks and stock options: AbbVie, Merck
William R. Short, MD, MPH, AAHIVS

Associate Professor of Medicine
Division of Infectious Diseases
Department of Medicine
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania

William R. Short, MD, MPH, AAHIVS: consultant/advisor/speaker: Janssen, ViiV.

Program Medium

This program has been made available online.

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Review the latest data on ART safety and tolerability in special populations in this slideset, from Clinical Care Options (CCO)

Jean Rene Anderson, MD Jill Blumenthal, MD, MAS Marta Boffito, MD, PhD, FRCP Jennifer Cocohoba Headshot Jennifer Cocohoba, PharmD Joseph J. Eron, Jr., MD Julian Falutz, MD, FRCPC Eric K. Farmer, PharmD, BCPS, AAHIVP Priscilla Y. Hsue, MD Jens D. Lundgren, MD, DMSc William R. Short, MD, MPH, AAHIVS Darcy Wooten, MD Released: November 28, 2022

Discussion of key considerations for switching antiretroviral therapy when the patient is pregnant, from Clinical Care Options (CCO)

person default Annette Haberl, MD William R. Short, MD, MPH, AAHIVS Released: November 23, 2022

Clinical Care Options (CCO) presents expert faculty discussing new data from AIDS 2022, from nursing perspectives

Joseph J. Eron, Jr., MD
Program Director
Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
person default Allison Webel, PhD, RN Mitchell J. Wharton, PhD, RN, FNP-BC, CNS, ACRN
Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: November 22, 2022 Expired: November 21, 2023

Prof Don Smith discusses new HIV data from IDWeek 2022 on long-acting cabotegravir plus rilpivirine in this commentary from Clinical Care Options (CCO)

Don Smith, MD Released: November 22, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings